by admin | Dec 14, 2018 | 2018, HPV, Milestones
2A Pharma has received approval from the UK Medicines and Healthcare products Regulatory Authority and from the local Ethics Committee to proceed with a first-in-human study of 2AP01, which is being developed as broad coverage prophylactic HPV vaccine formulated...
by admin | Sep 27, 2018 | 2018, Collaboration, Funding & Investments, Head & Neck Cancer, Milestones
We are extremely pleased to announce that 2A Pharma in collaboration with partners from The Danish Technological Institute and Danish biotech company DNA Sense have been granted EUR 653,000 Eurostars funding for 2AP07, a project to develop a therapeutic head...
by admin | Jun 25, 2018 | 2018, Funding & Investments, Milestones, Press Releases
2A Pharma is very pleased to announce that it has raised SEK 20 million (USD 2.2M) from existing and new investors. This funding augments the previously raised SEK 27 million (USD 3M) and will enable 2A Pharma to drive its leading vaccine candidate, 2AP01, a...
by admin | Dec 20, 2016 | 2016, Milestones, Press Releases
Medigene AG today announced that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus-like particles (AAVLPs) technology to 2A Pharma AB. [pdf-embedder...
by admin | Dec 20, 2016 | 2016, Funding & Investments, HPV, Milestones
2A Pharma AB today closed its first financing round, raising SEK 27 million from private angel investors. This new capital will enable us to take our first project, the AAVLP-HPV vaccine, through to the end of phase I clinical studies. We are grateful for our...
by admin | Dec 12, 2016 | 2016, Milestones
2A Pharma AB was incorporated in Sweden on 12 December 2016. Søren Nielsen, CEO: “This marks the formal beginning of a new exciting venture and the team is very excited about the journey ahead.”
Recent Comments